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Aims We examined the efficacy and safety of dapagliflozin, compared with placebo, according to aetiology in patients
with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in the Dapagliflozin And Prevention of
Adverse-outcomes in Heart Failure trial (DAPA-HF).
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Methods
and results
Aetiology was investigator-reported and categorized as ischaemic or non-ischaemic. The primary outcome was
the composite of an episode of worsening HF or cardiovascular death. A total of 4744 patients were randomized
in DAPA-HF, of whom 2674 (56.4%) patients had an ischaemic aetiology. Participants with an ischaemic aetiology
had a higher risk of cardiovascular mortality [hazard ratio (HR) 1.35, 95% confidence interval (CI) 1.13–1.63], but
lower risk of HF hospitalization (HR 0.83, 95% CI 0.70–0.98) than non-ischaemic patients. Compared with placebo,
dapagliflozin reduced the risk of worsening HF or cardiovascular death to a similar extent in both patients with
ischaemic and non-ischaemic aetiology (HR 0.77, 95% CI 0.65–0.92, and HR 0.71, 95% CI 0.58–0.87, respectively; P
for interaction = 0.55). Consistent benefits were observed for the components of the primary outcome and all-cause
mortality. Dapagliflozin, as compared with placebo, increased the proportion of patients with an improvement of
Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS) of ≥5 points (P for interaction = 0.32)
and decreased the proportion with a deterioration in KCCQ-TSS of ≥5 points (P for interaction = 0.76), irrespective
of aetiology. Study drug discontinuation and serious adverse events were similar according to treatment groups,
irrespective of aetiology.
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Conclusions Dapagliflozin reduced the risk of worsening HF and death, and improved symptoms, similarly in patients with ischaemic
and non-ischaemic aetiology. In addition, dapagliflozin was safe and well-tolerated, irrespective of aetiology.
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Graphical Abstract
Effects of dapagliflozin compared with placebo according to aetiology subgroups.
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Introduction
Over the past decades, a global transition in the aetiology of heart
failure (HF) with reduced ejection fraction (HFrEF) has occurred
from hypertension and rheumatic valvular disease to coronary
artery disease.1–8 Thus, in many parts of the world, coronary
artery disease has become the most common cause of HFrEF.
A distinction between ischaemic and non-ischaemic aetiology is
important for several reasons. First, certain evidence-based thera-
pies may be indicated in specific aetiologies, for example bypass
graft surgery for coronary artery disease.9 Second, HFrEF of
ischaemic origin may portend a worse prognosis than HFrEF due to
non-ischaemic causes.10–13 Third, the effectiveness of certain treat-




















. of the implantable cardioverter-defibrillator, cardiac resynchroniza-
tion therapy, and milrinone.14–17 It is, therefore, important to eval-
uate the effectiveness of new HFrEF treatments in both patients
with ischaemic and non-ischaemic aetiology.
In the Dapagliflozin And Prevention of Adverse-outcomes in
Heart Failure trial (DAPA-HF), the sodium–glucose co-transporter
2 (SGLT2) inhibitor, dapagliflozin, added to conventional guideline-
recommended therapies reduced the risk of worsening HF events,
cardiovascular death, and all-cause mortality, and improved symp-
toms, in 4744 patients with HFrEF with and without type 2
diabetes.18 The proposed improved myocardial energetics with
SGLT2 inhibition may suggest more benefit in patients with coro-
nary artery disease causing myocardial ischaemia.19–26 Likewise,
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any haemodynamic effects to improve loading conditions might
also be more beneficial in a patient with a propensity to myocardial
ischaemia. Other proposed mechanisms of action, e.g. improve-
ment in microvascular function and reduced fibrosis, may be more
important in patients with coronary disease (and patients with
diabetes who are more likely to have coronary disease).19–26 In
this pre-specified subgroup analysis of DAPA-HF, we investigated
the efficacy and safety of dapagliflozin compared with placebo
according to investigator-reported HF aetiology.
Methods
DAPA-HF was a randomized, double-blind, controlled trial in patients
with HFrEF, evaluating the efficacy and safety of dapagliflozin 10 mg
once daily compared with matching placebo, in addition to standard
care. The design, baseline characteristics, and primary results of the
trial are published.18,27 The ethics committee of each of the 410
participating institutions in 20 countries approved the protocol, and
all patients gave written informed consent. Drs. McMurray and Jhund
had full access to the trial data and take responsibility for its integrity
and the data analysis.
Study patients
Men and women aged 18 years or older with a diagnosis of HF for at
least 2 months were eligible if they were in New York Heart Asso-
ciation (NYHA) functional class II–IV, had a left ventricular ejection
fraction (LVEF) of ≤40%, were optimally treated with pharmacological
and device therapy for HF, and had an N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) concentration ≥600 pg/mL (≥400 pg/mL
if hospitalized for HF within the previous 12 months; ≥900 pg/mL if
atrial fibrillation or atrial flutter, irrespective of history of HF hospi-
talization). Key exclusion criteria included symptoms of hypotension
or systolic blood pressure <95 mmHg, estimated glomerular filtration
rate (eGFR) <30 mL/min/1.73 m2 or rapidly declining renal function,
type 1 diabetes, and other conditions likely to prevent patient partic-
ipation in the trial or greatly limit life expectancy. A complete list of
exclusion criteria is provided in the design paper.27 After randomiza-
tion, follow-up visits were scheduled at 14 and 60 days, and then at
120, 240, 360 days and every 4 months thereafter.
Investigator-reported aetiology
Data on HF aetiology were collected from the trial case report
form. Investigators were first asked whether the primary aetiol-
ogy was ischaemic, non-ischaemic, or unknown. If investigators
answered non-ischaemic, they were then asked to specify from
the following options (listed in this order): primary valvular, alco-
holic, hypertensive, peripartum, idiopathic, infectious, viral, diabetic,
drug-induced, arrhythmia, and other (please specify). The pre-specified
analysis of aetiology in DAPA-HF categorized patients as either
ischaemic or non-ischaemic, with unknown aetiology included in the
non-ischaemic category. We also conducted sensitivity analyses exclud-
ing patients with ‘unknown aetiology’, i.e. comparing only definite
ischaemic aetiology and non-ischaemic aetiology (without unknown
aetiology).
In the present analysis, we further subcategorized patients with
an investigator-reported non-ischaemic aetiology into hypertensive,




















































































The primary outcome was the composite of an episode of worsening
HF (HF hospitalization or urgent visit for worsening HF with admin-
istration of intravenous treatment for HF) or cardiovascular death,
whichever occurred first. In this analysis, secondary outcomes were
the occurrence of HF hospitalization or cardiovascular death; HF hos-
pitalization; cardiovascular death; death from any cause; recurrent HF
hospitalization or cardiovascular death; and change from baseline to
8 months in the total symptom score of the Kansas City Cardiomy-
opathy Questionnaire (KCCQ-TSS). Cause of death was adjudicated by
an independent committee using definitions reported in the Appendix
published with the primary results manuscript.18
Pre-specified safety analyses included adverse events leading to dis-
continuation of trial treatment and adverse events of interest, including
volume depletion, renal adverse events, bone fracture, amputation,
major hyperglycaemia, and diabetic ketoacidosis. Safety analyses were
performed in patients who had undergone randomization and received
at least one dose of either dapagliflozin or placebo (a total of eight
randomized patients were excluded from the safety analysis).
Statistical analyses
Patients were divided into two groups according to aetiology. Baseline
characteristics were summarized as frequencies with percentages,
means with standard deviation, or medians with interquartile ranges.
Differences in baseline characteristics were tested using the Chi-square
test for categorical variables and the Wilcoxon test and two-sample
t-test for non-normally and normally distributed continuous variables,
respectively.
Time-to-event data for the primary outcome and secondary
clinical outcomes according to aetiology, regardless of treatment
allocation, were evaluated using the Kaplan–Meier estimator and
cause-specific Cox proportional-hazards models, stratified according
to diabetes mellitus status, with a history of HF hospitalization and
treatment-group assignment as fixed-effect factors to calculate hazard
ratios (HRs), 95% confidence intervals (CIs), and two-sided P-values.
The models for all-cause death were not adjusted for a history of
HF hospitalization. In addition, adjusted HRs from models including
age, sex, geographical region, heart rate, systolic blood pressure,
body mass index, LVEF, NYHA functional class, NT-proBNP, atrial
fibrillation, and eGFR were reported. To address the competing risk
of death, Fine–Gray competing risk analyses were performed to
compare the risk of outcomes (except for all-cause death) according
to aetiology. For the HF hospitalization outcome, death from any cause
was considered a competing risk, while non-cardiovascular death was
considered a competing risk for the rest of the outcomes. Subdistri-
bution HRs, adjusted for the same variables as the cause-specific Cox
regression models, with 95% CIs were reported.
To compare the effects of dapagliflozin vs. placebo on the pri-
mary outcome and secondary clinical outcomes in patients with
ischaemic and non-ischaemic aetiology, respectively, time-to-event
data were evaluated with the Kaplan–Meier estimator and Cox
proportional-hazards models, stratified according to diabetes melli-
tus status, with a history of HF hospitalization and treatment-group
assignment as fixed-effect factors. The models for all-cause death were
not adjusted for a history of HF hospitalization. Total, including recur-
rent events were evaluated with semiparametric proportional-rates
models.28 The difference between treatment groups in the change in
KCCQ-TSS from baseline to 8 months in surviving patients accord-
ing to aetiology was analysed using two-sample t-test. Responder
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analyses examining proportions of patients with a deterioration (i.e.
decrease in KCCQ-TSS of ≥5 points) and clinically important improve-
ment (i.e. an increase of KCCQ-TSS of ≥5 points) in KCCQ at
8 months according to aetiology were conducted with the treat-
ment effect expressed as an odds ratio (OR) using methods previously
described.29
The efficacy of dapagliflozin according to aetiology in patients
with and without diabetes separately was also examined; Cox
proportional-hazards models for the time-to-event analyses were not
stratified according to diabetes mellitus status.
Finally, the effect of dapagliflozin on the primary outcome according
to continuous LVEF as a fractional polynomial was examined in patients
with and without an ischaemic aetiology separately.
All analyses were conducted using STATA version 16.1 (Stata Corp.,
College Station, TX, USA) and SAS version 9.4 (SAS Institute, Cary,
NC, USA). A P-value of 0.05 was considered statistically significant.
Sensitivity analyses
In the main analyses, patients with an investigator-reported unknown
aetiology were categorized as non-ischaemic aetiology. However, to
test for the robustness of our findings, we performed sensitivity
analyses in which these patients were excluded.
Results
Patient characteristics
Of the 4744 patients randomized in DAPA-HF, 2674 patients
(56.4%) had an ischaemic aetiology, as reported by investigators,
and 2070 (43.6%) had a non-ischaemic aetiology [1687 (35.6%) with
known non-ischaemic aetiology and 383 (8.1%) with ‘unknown’
aetiology, assumed to be non-ischaemic, as pre-specified in the
analysis plan]. Baseline characteristics according to aetiology are
presented in Table 1. Compared with patients with non-ischaemic
aetiology, those with ischaemic aetiology were older, more often
male and white, more likely to have a previous myocardial infarc-
tion, prior coronary revascularization, peripheral artery disease,
carotid artery stenosis, angina, hypertension, and type 2 diabetes,
but less likely to have a history of atrial fibrillation or prior hospital-
ization for HF. Patients with ischaemic aetiology had a higher mean
systolic blood pressure and ejection fraction, but had a lower mean
heart rate and eGFR, as well as worse NYHA functional class over-
all. With respect to background HF therapy, patients with ischaemic
aetiology were less frequently treated with digoxin and angiotensin
receptor–neprilysin inhibitors and more often with implantable
cardioverter-defibrillator. A detailed breakdown of aetiology is
provided in online supplementary Table S1, both overall and by
geographical region. An ischaemic aetiology was the single most
common aetiology reported overall (56.4% of all patients) and was
somewhat more common in Europe than other regions. Among the
non-ischaemic aetiologies, idiopathic was the most common overall
(17.6% of all patients) and was least common in Europe, compared
with other regions. Overall, 8.1% of patients had an ‘unknown
aetiology’ and this proportion ranged from 6.0% to 11.0% across
regions. Other reported aetiologies individually accounted for <5%



















































































.. Outcomes according to aetiology
Primary and secondary outcomes according to aetiology
Patients with and without an ischaemic aetiology had a similar
risk of worsening HF or cardiovascular death when compared
in a multivariable cause-specific Cox proportional-hazards model
(reference non-ischaemic group; HR 1.01, 95% CI 0.88–1.15).
The risk of HF hospitalization was significantly lower in patients
with ischaemic aetiology compared to those with non-ischaemic
aetiology, whereas the risk of cardiovascular death and death
from any cause was significantly higher in patients with ischaemic
aetiology, even after adjustment for other prognostic variables
including NT-proBNP (online supplementary Table S2). Fine–Gray
competing risk analyses, accounting for the competing risk of death,
yielded similar findings (online supplementary Table S2).
Adjudicated causes of death according to aetiology
Adjudicated causes of death according to ischaemic and
non-ischaemic aetiology are shown in Figure 1. Overall, the
two main modes of cardiovascular death were sudden death and
death due to worsening HF (‘pump failure’). While the proportion
of deaths that were sudden was similar in the ischaemic and
non-ischaemic groups, fewer ischaemic patients, compared to
non-ischaemic patients, had a death attributed to worsening HF.
Conversely, the proportion of deaths attributed to myocardial
infarction was higher in patients with an ischaemic aetiology,
compared to patients with a non-ischaemic aetiology, although
the proportion of deaths due to myocardial infarction was small
in both subgroups. The cause of death was undetermined in just
under one fifth of cases (these deaths were presumed to be car-
diovascular) and this proportion was similar in the ischaemic and
non-ischaemic groups, as was the proportion of deaths attributed
to non-cardiovascular causes (which accounted for about one in
seven deaths).
Effects of dapagliflozin according
to aetiology
Primary composite outcome
Dapagliflozin reduced the risk of worsening HF or cardiovascular
death to the same extent in patients with an ischaemic aetiology
(HR 0.77, 95% CI 0.65–0.92) and without an ischaemic aetiology
(HR 0.71, 95% CI 0.58–0.87), with no interaction between aetiol-
ogy and effect of treatment (P for interaction = 0.55) (Table 2 and
Figure 2).
Secondary outcomes
Hazard ratios, rate ratios, and ORs for the effect of dapagliflozin
compared with placebo on the secondary clinical endpoints are
displayed in Table 2 and Figure 3. The effect of dapagliflozin
was consistent in patients with and without an ischaemic
aetiology for all secondary endpoints: HF hospitalization or
cardiovascular death (P for interaction = 0.45), HF hospital-
ization (P for interaction = 0.73), cardiovascular death (P for
interaction= 0.13), death from any cause (P for interaction= 0.10),
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics of the study population according to aetiology
Ischaemic (n = 2674) Non-ischaemic (n = 2070) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years), mean (SD) 67.7 (9.8) 64.6 (11.9) <0.001
Sex, n (%) <0.001
Female 538 (20.1) 571 (27.6)
Male 2136 (79.9) 1499 (72.4)
Race, n (%) <0.001
Asian 541 (20.2) 575 (27.8)
Black 66 (2.5) 160 (7.7)
White 2043 (76.4) 1290 (62.3)
Other 24 (0.9) 45 (2.2)
Geographic region, n (%) <0.001
Asia/Pacific 529 (19.8) 567 (27.4)
Europe 1404 (52.5) 750 (36.2)
North America 351 (13.1) 326 (15.7)
South America 390 (14.6) 427 (20.6)
Physiologic measures
Systolic blood pressure (mmHg), mean (SD) 122.9 (15.8) 120.3 (16.8) <0.001
Diastolic blood pressure (mmHg), mean (SD) 73.3 (9.9) 73.8 (11.2) 0.12
Heart rate (bpm), mean (SD) 70.1 (11.0) 73.4 (12.3) <0.001
BMI (kg/m2), mean (SD) 28.1 (5.4) 28.2 (6.6) 0.41
Creatinine (μmol/L), mean (SD) 106.7 (30.2) 101.6 (30.4) <0.001
Glycated haemoglobin (%), mean (SD) 6.6 (1.4) 6.4 (1.3) <0.001
eGFR (mL/min/1.73 m2), mean (SD) 63.7 (18.5) 68.4 (20.2) <0.001
eGFR (mL/min/1.73 m2), n (%) <0.001
<60 1174 (43.9) 752 (36.3)
≥60 1498 (56.1) 1318 (63.7)
NT-proBNP for AF on ECG (pg/mL), median (IQR) 2083 (1298–3270) 1878 (1224–3145) 0.16
NT-proBNP for no AF on ECG (pg/mL), median (IQR) 1264 (766–2353) 1345 (778–2510) 0.12
LVEF (%), mean (SD) 31.7 (6.5) 30.2 (7.1) <0.001
NYHA class, n (%) <0.001
II 1742 (65.1) 1461 (70.6)
III 914 (34.2) 584 (28.2)
IV 18 (0.7) 25 (1.2)
KCCQ, mean (SD)
Total symptom score 73.2 (21.1) 74.1 (22.6) 0.18
Clinical summary score 70.7 (20.2) 71.7 (21.5) 0.10
Overall summary score 67.9 (20.2) 68.6 (21.3) 0.28
Medical history, n (%)
Hypertensiona 2156 (80.6) 1367 (66.0) <0.001
Type 2 diabetes 1333 (49.9) 806 (38.9) <0.001
Atrial fibrillation 894 (33.4) 924 (44.6) <0.001
Hospitalization for HFb 1232 (46.1) 1019 (49.2) 0.03
Previous MI 1939 (72.5) 153 (7.4) <0.001
Previous PCI 1449 (54.2) 175 (8.5) <0.001
Previous CABG 737 (27.6) 62 (3.0) <0.001
Ischaemic stroke 287 (10.7) 151 (7.3) <0.001
Peripheral artery disease 509 (19.0) 140 (6.8) <0.001
Angina 937 (35.0) 175 (8.5) <0.001
Vascular stent 106 (4.0) 17 (0.8) <0.001
Carotid artery stenosis 205 (7.7) 46 (2.2) <0.001
Treatment, n (%)
ACEI 1545 (57.8) 1116 (53.9) 0.008
ARB 717 (26.8) 590 (28.5) 0.20
ARNI 260 (9.7) 248 (12.0) 0.01
Beta-blocker 2567 (96.0) 1991 (96.2) 0.74
MRA 1898 (71.0) 1472 (71.1) 0.92
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Table 1 (Continued)
Ischaemic (n = 2674) Non-ischaemic (n = 2070) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diuretic 2250 (84.1) 1758 (84.9) 0.46
Digoxin 381 (14.2) 506 (24.4) <0.001
Oral anticoagulantc 995 (37.2) 974 (47.1) <0.001
Antiplateletd 1928 (72.1) 664 (32.1) <0.001
Statin 2232 (83.5) 944 (45.6) <0.001
ICD 591 (22.1) 362 (17.5) <0.001
ICD/CRT-D 749 (28.0) 493 (23.8) 0.001
CRT-P/CRT-D 183 (6.8) 171 (8.3) 0.07
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BMI, body mass index; CABG,
coronary artery bypass grafting; CRT-D, cardiac resynchronization therapy-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; ECG, electrocardiogram; eGFR,
estimated glomerular filtration rate; HF, heart failure; ICD, implantable cardioverter-defibrillator; IQR, interquartile range; KCCQ, Kansas City Cardiomyopathy Questionnaire;
LVEF, left ventricular ejection fraction; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA,
New York Heart Association; PCI, percutaneous coronary intervention; SD, standard deviation.
aA history of hypertension.
bAny time prior to randomization (a key exclusion criterion was a hospitalization due to decompensated HF <4 weeks prior to enrolment).
cVitamin K antagonists (warfarin/coumadin) and direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban).
dAspirin, ADP receptor inhibitors (clopidogrel, ticagrelor, prasugrel), and adenosine reuptake inhibitors (dipyridamole).
Figure 1 Adjudicated causes of death according to ischaemic and non-ischaemic aetiology. CV, cardiovascular; MI, myocardial infarction.
and recurrent HF hospitalization or cardiovascular death (P for
interaction = 0.19).
The mean increase in KCCQ-TSS from baseline to 8 months
was significantly greater with dapagliflozin in both the ischaemic
and non-ischaemic subgroups (P for interaction = 0.40). The
proportion of patients with an improvement of KCCQ-TSS of
≥5 points was greater with dapagliflozin, compared with placebo,
in both patients with an ischaemic aetiology (58.3% vs. 49.5%;
OR 1.19, 95% CI 1.09–1.29) and without an ischaemic aetiology
(58.3% vs. 52.9%; OR 1.11, 95% CI 1.01–1.22) (P for inter-
action = 0.32). Conversely, the proportion of patients with a
decrease in KCCQ-TSS of ≥5 points was smaller in those treated
with dapagliflozin, compared with placebo, in both patients with




















.. a non-ischaemic aetiology (25.5% vs. 32.3%; OR 0.85, 95% CI
0.76–0.94) (P for interaction = 0.76).
Non-ischaemic aetiology subgroups
Among the 2070 patients with non-ischaemic HFrEF, investigators
reported the aetiology as hypertensive in 262 (12.7%), idiopathic
in 833 (40.2%), other miscellaneous causes in 592 (28.6%), and
‘unknown’ in 383 (18.5%). Data on the effect of dapagliflozin com-
pared with placebo on secondary endpoints and the occurrence of
the pre-specified adverse events according to these non-ischaemic
subgroups are shown in online supplementary Tables S3 and S4,
respectively. In line with the main findings, dapagliflozin, compared
with placebo, reduced the risk of worsening HF, cardiovascular
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Effects of dapagliflozin compared with placebo on clinical events according to aetiology
Outcome Ischaemic (n = 2674) Non-ischaemic (n = 2070) P-value for
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Worsening HF event or cardiovascular death 0.55
n (%) 289 (21.3) 223 (16.9) 213 (21.0) 163 (15.4)
Event rate per 100 person-years (95% CI) 15.6 (13.9–17.5) 11.9 (10.5–13.6) 15.6 (13.6–17.8) 11.1 (9.5–12.9)
HR (95% CI) 0.77 (0.65–0.92) 0.71 (0.58–0.87)
HF hospitalization or cardiovascular death 0.45
n (%) 284 (20.9) 222 (16.9) 211 (20.8) 160 (15.1)
Event rate per 100 person-years (95% CI) 15.2 (13.6–17.1) 11.9 (10.4–13.5) 15.4 (13.4–17.6) 10.9 (9.3–12.7)
HR (95% CI) 0.78 (0.65–0.93) 0.70 (0.57–0.86)
HF hospitalization 0.73
n (%) 173 (12.7) 118 (9.0) 145 (14.3) 113 (10.7)
Event rate per 100 person-years (95% CI) 9.3 (8.0–10.8) 6.3 (5.3–7.6) 10.6 (9.0–12.4) 7.7 (6.4–9.2)
HR (95% CI) 0.68 (0.54–0.86) 0.72 (0.57–0.92)
Cardiovascular death 0.13
n (%) 170 (12.5) 152 (11.6) 103 (10.2) 75 (7.1)
Event rate per 100 person-years (95% CI) 8.6 (7.4–10.0) 7.8 (6.7–9.2) 7.0 (5.8–8.5) 4.8 (3.9–6.1)
HR (95% CI) 0.92 (0.74–1.14) 0.69 (0.51–0.93)
All-cause death 0.10
n (%) 206 (15.2) 185 (14.1) 123 (12.1) 91 (8.6)
Event rate per 100 person-years (95% CI) 10.4 (9.1–11.9) 9.5 (8.3–11.0) 8.4 (7.0–10.0) 5.9 (4.8–7.2)
HR (95% CI) 0.92 (0.76–1.12) 0.70 (0.53–0.92)
Recurrent HF hospitalization or cardiovascular death 0.19
No. of events 407 328 335 239
RR (95% CI) 0.82 (0.68–1.00) 0.67 (0.53–0.85)
KCCQ-TSS
Change in KCCQ-TSS score at 8 months 3.0 (1.9–4.0) 6.5 (5.4–7.6) 3.8 (2.4–5.1) 5.6 (4.4–6.9) 0.40
≥5-point improvement in KCCQ-TSS at
8 months
0.32
Proportion of patients 49.5% 58.3% 52.9% 58.3%
OR (95% CI) 1.19 (1.09–1.29) 1.11 (1.01–1.22)
≥5-point decrease in KCCQ-TSS at
8 months
0.76
Proportion of patients 33.3% 25.2% 32.3% 25.5%
OR (95% CI) 0.83 (0.76–0.90) 0.85 (0.76–0.94)
CI, confidence interval; HF, heart failure; HR, hazard ratio; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score; OR, odds ratio; RR, rate ratio.
death, and all-cause death, improved symptoms, and was safe and
well-tolerated, across all non-ischaemic subgroups.
Aetiology and diabetes
Data on the effects of dapagliflozin compared with placebo in
patients with ischaemic and non-ischaemic aetiology according to
diabetes status are shown in online supplementary Table S5. In
line with the main findings, dapagliflozin, compared with placebo,
reduced the risk of worsening HF, cardiovascular death, and
all-cause death and improved symptoms, irrespective of aetiology,
in both patients with and without diabetes.
Aetiology and left ventricular ejection fraction
The benefit of dapagliflozin on worsening HF or cardiovascular























. with and without an ischaemic aetiology (P for interaction = 0.37
and 0.62, respectively) (online supplementary Figure S1).
Sensitivity analyses
We excluded patients with aetiology reported as ‘unknown’ by the
investigator from the analyses. Baseline characteristics according
to aetiology are presented in online supplementary Table S6. Data
on the effect of dapagliflozin compared with placebo on secondary
endpoints and the occurrence of the pre-specified adverse events
in patients with ischaemic and non-ischaemic aetiology are shown
in online supplementary Tables S7 and S8, respectively. In line with
the main findings, dapagliflozin, compared with placebo, reduced
the risk of worsening HF, cardiovascular death, and all-cause death,
improved symptoms, and was safe and well-tolerated, irrespective
of aetiology.
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Figure 2 Primary outcome (worsening heart failure or cardiovascular death) according to randomized treatment assignment in ischaemic
(A) and non-ischaemic (B) patient subgroups.
Safety analyses
The pre-specified adverse events according to treatment assign-
ment in patients with and without an ischaemic aetiology are shown
in Table 3. In general, the proportions of patients who discontinued
trial treatment or experienced adverse events according to
treatment assignment were similar, irrespective of aetiology.
Discussion
In this pre-specified analysis of DAPA-HF, the risk of cardiovas-
cular death and all-cause death was higher in patients with an
ischaemic aetiology compared to those with a non-ischaemic aeti-
ology, whereas the risk of HF hospitalization was lower in patients
with ischaemic aetiology. Furthermore, dapagliflozin, added to con-
ventional guideline-recommended therapies, reduced the risk of
worsening HF events, cardiovascular death, and all-cause death, and
improved symptoms, to a similar extent in both patients with and
without an ischaemic aetiology.
Baseline characteristics and outcomes
according to aetiology
The proportion of patients with an investigator-reported ischaemic
aetiology was similar to that of four recent HFrEF trials.13,30–32
The present analysis of DAPA-HF demonstrated substantial dif-
ferences in the clinical profile between HFrEF patients with and
without an ischaemic aetiology, most of which confirmed prior
findings.13 In DAPA-HF, patients with ischaemic aetiology were
older, more often male and white and had a slightly higher ejec-
tion fraction and symptom burden than those with non-ischaemic
aetiology. As expected, patients with an ischaemic aetiology were
also more likely to have a previous myocardial infarction, prior
coronary revascularization, and type 2 diabetes and were more
frequently treated with antiplatelet agents, statins, and implantable





















































. proportion of patients with non-ischaemic aetiology who were
treated with antiplatelet agents and statins. Although data on the
indications for prescribing these drugs were not available, it most
likely reflects that approximately 40% and 7% of patients with
non-ischaemic aetiology had type 2 diabetes and peripheral artery
disease, respectively. However, the evidence that statins are ben-
eficial in HF patients with or without coronary artery disease is
lacking.33,34 The same is likely true of antiplatelet agents, and other
antithrombotic therapies are not beneficial in HFrEF.35,36
Previous studies investigating outcomes according to aetiol-
ogy found HFrEF of non-ischaemic origin to be associated with
better outcomes than HFrEF due to an ischaemic cause.10–12
However, in a recent analysis from the Prospective Com-
parison of Angiotensin Receptor Neprilysin Inhibitor With
Angiotensin-Converting-Enzyme Inhibitor to Determine Impact on
Global Mortality and Morbidity in Heart Failure (PARADIGM-HF),
aetiology did not appear to significantly modify the risk of the
primary composite outcome of HF hospitalization or cardiovas-
cular death.13 In keeping with PARADIGM-HF, we found that the
risk of the composite of worsening HF or cardiovascular death
did not differ by aetiology in a contemporary, globally represen-
tative, and well-treated cohort of patients with HFrEF enrolled in
DAPA-HF. There are several plausible explanations to this differ-
ence. First, our analyses were adjusted for important prognostic
variables, including natriuretic peptides. Second, patients with
ischaemic aetiology enrolled in DAPA-HF (and PARADIGM-HF)
were more aggressively treated with antiplatelet agents, statins,
and beta-blockers, and more often had undergone coronary revas-
cularization. Third, HFrEF patients with severely reduced kidney
function (eGFR <30 mL/min/1.73 m2) more often have HF due to
ischaemic causes; as these patients are excluded from most clinical
trials (including DAPA-HF), it is possible that the risk of death
and HF hospitalization in patients with ischaemic aetiology may
have been underestimated. However, this apparent similarity in the
composite outcome in DAPA-HF masked a directional difference
in its HF hospitalization and cardiovascular mortality components.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Pre-specified secondary outcomes according to randomized treatment assignment in ischaemic and non-ischaemic patient
subgroups. HF, heart failure.
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Table 3 Adverse events of dapagliflozin compared with placebo according to aetiology
Adverse event Ischaemic (n = 2670) Non-ischaemic (n = 2066) P-value for
interaction
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Discontinuation of study drug for
any reason
153 (11.3) 139 (10.6) 105 (10.4) 110 (10.4) 0.68
Discontinuation of study drug due to
adverse event
64 (4.7) 67 (5.1) 52 (5.1) 44 (4.2) 0.28
Volume depletion 87 (6.4) 100 (7.6) 75 (7.4) 78 (7.4) 0.45
Renal adverse event 101 (7.4) 83 (6.3) 69 (6.8) 70 (6.6) 0.52
Fracture 32 (2.4) 27 (2.1) 18 (1.8) 22 (2.1) 0.46
Amputation 10 (0.7) 11 (0.8) 2 (0.2) 2 (0.2) 0.88
Major hypoglycaemia 1 (0.1) 2 (0.2) 3 (0.3) 2 (0.2) 0.44
Diabetic ketoacidosis 0 (0.0) 3 (0.2) 0 (0.0) 0 (0.0) N/A
N/A, not applicable.
A total of eight randomized patients were excluded from the safety analysis, as these were performed in patients who had undergone randomization and received at least one
dose of dapagliflozin or placebo.
Patients with an ischaemic aetiology had a greater risk of car-
diovascular death and all-cause mortality, but a lower risk of HF
hospitalization than those with non-ischaemic aetiology. While
the lower rate of HF hospitalization in ischaemic patients could
reflect the competing risk of death, the lower hospitalization rate
in ischaemic patients persisted when accounting for the competing
risk of death in competing risk analyses. Although the explanations
to this finding are not clear, patients with a non-ischaemic aetiology
are a heterogeneous group and it is possible that individuals with
certain aetiologies may have a better or worse prognosis than the
more common aetiologies.
As expected, the proportion of deaths attributed to myocardial
infarction was higher in patients with an ischaemic aetiology com-
pared to patients with a non-ischaemic aetiology. Perhaps more
surprisingly, the proportion of deaths that were sudden was simi-
lar in the ischaemic and non-ischaemic groups. While patients with
non-ischaemic HF may be less prone to sudden death from ventric-
ular tachyarrhythmias than patients with ischaemic HF, electrome-
chanical dissociation, asystole, or a terminal bradyarrhythmia as the
cause of sudden death may be relatively more common in patients
with a non-ischaemic cardiomyopathy.37–39 Our finding of a similar
proportion of sudden deaths in the ischaemic and non-ischaemic
groups is in line with previous data,40 though the proportion was
overall lower in the present analysis. The lower proportion of
sudden deaths likely reflects the reduction in sudden death in
patients with HF due to improved medical and device therapy.41
Another interesting observation was that fewer ischaemic patients,
compared to non-ischaemic patients, had a death attributed to
worsening HF. Although there is no clear explanation, it is possible
this reflects the higher ejection fraction in the ischaemic group.
Efficacy and safety of dapagliflozin
according to aetiology
While aetiology does not appear to modify the effects of renin–





















































. or mineralocorticoid receptor antagonists in patients with
HFrEF,13,42–49 patients with ischaemic aetiology may respond differ-
ently to certain HFrEF treatments than those with non-ischaemic
aetiology. Prophylactic implantable cardioverter-defibrillator
implantation has been shown to reduce the rate of sudden cardiac
death and all-cause mortality in HFrEF due to ischaemic heart
disease, but not in HFrEF due to non-ischaemic causes.14,50–52
On the other hand, HFrEF patients with non-ischaemic aetiology
may achieve greater improvements of left ventricular function
and remodelling with cardiac resynchronization therapy than
those with an ischaemic aetiology.16,17 Likewise, treatment with
intravenous milrinone in the acute setting may be associated
with better outcomes in patients with non-ischaemic aetiology
and worse outcomes in those with ischaemic aetiology.15 These
differences underline the importance of investigating the efficacy
and safety of new HF treatments according to aetiology. In this
pre-specified analysis of DAPA-HF, dapagliflozin reduced the risk of
the primary outcome similarly in patients with both ischaemic and
non-ischaemic aetiology. In addition, the efficacy of dapagliflozin
on HF hospitalization (both first and recurrent), cardiovascular
death, and all-cause death was consistent, irrespective of aetiology.
Key goals of management of patients with HFrEF are not only
to prevent hospital admissions and reduce mortality, but also
to reduce patients’ symptom burden and improve their physical
function and quality of life. Importantly, this study demonstrated
that dapagliflozin considerably increased the mean KSSQ-TSS at
8 months in both patients with ischaemic and non-ischaemic aeti-
ology. Moreover, dapagliflozin increased the proportion of patients
with a clinically meaningful improvement in symptoms (increase
in KCCQ-TSS of ≥5 points) at 8 months and reduced the pro-
portion with a clinically meaningful deterioration (decrease in
KCCQ-TSS of ≥5 points), irrespective of aetiology. Collectively,
these data underline the substantial, and clinically important, ben-
efits of dapagliflozin, irrespective of aetiology, in HFrEF patients
receiving optimal guideline-directed medical therapy and provide
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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further evidence for dapagliflozin as a new treatment option for
HFrEF. Interestingly, despite the different mortality and hospitaliza-
tion profiles of ischaemic and non-ischaemic patients, their symp-
tom and health status changes over time seemed to be similar.
Data on safety and tolerability in DAPA-HF were also reas-
suring. Overall, study drug discontinuation and serious adverse
events were generally uncommon with no differences by aetiol-
ogy. Further, study drug discontinuation and serious adverse events
were not more frequently reported in the dapagliflozin group
than in the placebo group in both patients with ischaemic and
non-ischaemic aetiology. These data further underline the safety
and tolerability of dapagliflozin in patients with HFrEF, irrespective
of aetiology.
Limitations
The findings of this study should be viewed in the context of
potential limitations. Although aetiology was a pre-defined sub-
group analysis, the assessment of secondary clinical outcomes by
aetiology was done post-hoc. The pre-specified inclusion and exclu-
sion criteria precluded the enrolment of hospitalized and other
very high-risk patients, which might affect the generalizability of
our results. Some degree of misclassification of HF aetiology can-
not be precluded as aetiology was investigator-reported and no
specific instructions as to how to identify aetiology were pro-
vided. Moreover, 8% of the study population had an undetermined
HF aetiology, which may reflect that patients may not have been
comprehensively examined for specific causes of HF, but also the
difficulties of ascribing an ischaemic aetiology, even with coronary
angiography.53 In addition, it is possible that some patients with
HF can have mixed aetiologies, which are not mutually exclusive.
Moreover, it was not possible to examine outcomes according to
specific groups of non-ischaemic aetiology other than the idiopathic
and hypertensive categories due to the small number of events.
Also, while it would have been interesting to evaluate the effect
of dapagliflozin on LVEF according to aetiology, echocardiography
was not performed routinely during follow-up in DAPA-HF. Finally,
further studies on sudden deaths according to aetiology in HFrEF
are warranted, given the similar proportion of sudden deaths in the
ischaemic and non-ischaemic groups in DAPA-HF and the lack of
detailed data regarding the causes of sudden death.
Conclusions
In DAPA-HF, dapagliflozin, compared with placebo, reduced the
risk of worsening HF events and death, and improved symptoms,
similarly in patients with ischaemic and non-ischaemic aetiology.
These findings provide further evidence for dapagliflozin as a new
treatment option for HFrEF.
Supplementary Information
Additional supporting information may be found online in the
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